The company, formerly known as GlaxoSmithKline, plans to invest in the site there through 2025, including building new facilities and assembly lines.
The company will also undertake a £67 million refurbishment of one of its Montrose factories in Scotland, with the investment to be used to ramp up production of compounds used in its medicines.
The Mail on Sunday newspaper told Global Supply Director Regis Simard that the company has a proud tradition of manufacturing innovative medicines in the UK.
He said: “Our six UK manufacturing sites, including Montrose, are an important part of our global manufacturing network and are leveraging science, technology and skills to deliver medicines faster and more efficiently. We are continuing to invest.”
GSK has had a strong year, now valued at £65bn, with its share price up 9% on last year, and despite falling sales of COVID-19 drugs, it has twice revised its full-year profit forecast for 2023. I pulled it up.
Last Tuesday (9 January), the company also announced the acquisition of biopharmaceutical group Aeolus in a deal worth up to £1.1bn.
The companies said GSK would acquire Aiolos, which is focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory diseases, for $1.1 billion upfront and regulatory and regulatory support based on certain successes. The company has entered into an agreement to acquire the company for up to $400 million in milestone payments. .
With this acquisition, the company announced that Ailos' AIO, which is said to be a “potentially best-in-class long-acting anti-thymic stromal lymphopoietin (TLSP) monoclonal antibody that is ready to enter Phase 2 clinical trials,” It states that access to 001 will be possible. Developments to treat adults with asthma. Additional indications include chronic sinusitis with nasal polyps.
It was exclusively licensed to Aeolus outside Greater China by Jiangsu Hengrui Pharmaceutical Co., Ltd. (Hengrui).
Tony Wood, Chief Scientific Officer at GSK, said: “We have a proud heritage and deep development expertise in respiratory medicine, specifically addressing diseases driven by IL-5 with high levels of eosinophils or high T2 inflammation. Targeting the TSLP pathway The addition of AIO-001, a potentially best-in-class medicine, has the potential to expand the scope of our current respiratory biologics portfolio, which includes therapeutic options for which This could include as many as 40% of patients with severe asthma, who have much-needed low T2 inflammation.”
GSK has a leading portfolio of over-the-counter and investigational medicines to address a range of respiratory diseases, including biologics aimed at treating subsets of asthma patients with high levels of eosinophils or high T2 inflammation. I have a portfolio. AIO-001 enables GSK's respiratory portfolio to offer biologic options to a broader segment of the 315 million asthma patients regardless of biomarker status, including those with low T2 inflammation. There is a gender.
Frem Farouk, CEO of Aiolos Bio, said: “We believe this transaction speaks to the high potential of our long-acting anti-TSLP monoclonal antibody AIO-001. Decades of experience in respiratory therapy development and a shared commitment to improving patient lives We are confident that by partnering with GSK, a leader in this field, we will be able to rapidly advance this therapy with the hope of significantly reducing the treatment burden for patients.”
GSK chief executive Dame Emma Walmsley praised the UK economy earlier this month, saying the country was “uniquely placed” to perform well in life sciences, the Mail reported. Mr Walmsley said the UK stood out from other countries because of its high academic standards, high-profile companies and NHS.
Additionally, in September last year, GSK opened a new £65 million pharmaceutical factory in Hertfordshire to rapidly produce medicines developed through its research pipeline.